TARS
Price:
$30.59
Market Cap:
$1.16B
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceutical...[Read more]
Industry
Biotechnology
IPO Date
2020-10-16
Stock Exchange
NASDAQ
Ticker
TARS
According to Tarsus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.30. This represents a change of 20.61% compared to the average of -6.05 of the last 4 quarters.
The mean historical PE Ratio of Tarsus Pharmaceuticals, Inc. over the last ten years is -37.97. The current -7.30 PE Ratio has changed 1.82% with respect to the historical average. Over the past ten years (40 quarters), TARS's PE Ratio was at its highest in in the June 2021 quarter at 23.47. The PE Ratio was at its lowest in in the September 2019 quarter at -82.36.
Average
-37.97
Median
-32.39
Minimum
-85.97
Maximum
-4.38
Discovering the peaks and valleys of Tarsus Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 28.58%
Maximum Annual PE Ratio = -4.38
Minimum Annual Increase = -82.62%
Minimum Annual PE Ratio = -85.97
Year | PE Ratio | Change |
---|---|---|
2023 | -4.38 | -24.67% |
2022 | -5.81 | -82.62% |
2021 | -33.45 | 6.76% |
2020 | -31.33 | -63.56% |
2019 | -85.97 | 28.58% |
The current PE Ratio of Tarsus Pharmaceuticals, Inc. (TARS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-14.55
5-year avg
-32.19
10-year avg
-37.97
Tarsus Pharmaceuticals, Inc.’s PE Ratio is less than LianBio (-0.39), greater than Aldeyra Therapeutics, Inc. (-9.62), less than Travere Therapeutics, Inc. (-5.83), greater than Eton Pharmaceuticals, Inc. (-17.69), less than Connect Biopharma Holdings Limited (-3.00), less than Acumen Pharmaceuticals, Inc. (-2.06), less than Nuvation Bio Inc. (-1.34), less than Eledon Pharmaceuticals, Inc. (-1.43), less than Opthea Limited (-1.11), greater than Centessa Pharmaceuticals plc (-9.93), greater than Nuvalent, Inc. (-32.10), less than Genfit S.A. (-4.29), less than Monte Rosa Therapeutics, Inc. (-3.11), less than Design Therapeutics, Inc. (-5.23), less than Werewolf Therapeutics, Inc. (-1.64), less than Ikena Oncology, Inc. (-1.22), greater than Stoke Therapeutics, Inc. (-7.92), less than PepGen Inc. (-3.22), greater than Tyra Biosciences, Inc. (-14.94), less than Entrada Therapeutics, Inc. (4.84), greater than Pharvaris N.V. (-8.20), less than Rallybio Corporation (-0.66),
Company | PE Ratio | Market cap |
---|---|---|
-0.39 | $34.47M | |
-9.62 | $364.25M | |
-5.83 | $839.88M | |
-17.69 | $118.59M | |
-3.00 | $68.88M | |
-2.06 | $133.38M | |
-1.34 | $692.60M | |
-1.43 | $100.73M | |
-1.11 | $444.73M | |
-9.93 | $1.62B | |
-32.10 | $5.59B | |
-4.29 | $206.63M | |
-3.11 | $349.21M | |
-5.23 | $264.42M | |
-1.64 | $88.28M | |
-1.22 | $81.56M | |
-7.92 | $773.92M | |
-3.22 | $287.77M | |
-14.94 | $1.09B | |
4.84 | $550.55M | |
-8.20 | $1.03B | |
-0.66 | $45.64M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tarsus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Tarsus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Tarsus Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Tarsus Pharmaceuticals, Inc. (TARS)?
What is the highest PE Ratio for Tarsus Pharmaceuticals, Inc. (TARS)?
What is the 3-year average PE Ratio for Tarsus Pharmaceuticals, Inc. (TARS)?
What is the 5-year average PE Ratio for Tarsus Pharmaceuticals, Inc. (TARS)?
How does the current PE Ratio for Tarsus Pharmaceuticals, Inc. (TARS) compare to its historical average?